Dr. Pierre Kory the medical director of the trauma and life support center at the University of Wisconsin, a board-certified critical medicine, pulmonary diseases, and internal medicine doctor, shared my sentiments. In testimony in front of the Senate on December 7th, he questioned the CDC and the NIH in their dissemination of medical information including the idea that they have promoted only expensive experimental drugs including the vaccine.
He takes it one step further in explaining to the board that he has mountains of evidence about an older long-used drug, Ivermectin. He states that, the research and evidence comes from some of the most published doctors in the nation and world. A drug he calls “a solution to this crisis…. It basically obliterates the transmission of this virus. If you take it (prophylactically) you will not get sick.” Here is his testimony
But the drug remains unapproved for use in the treatment of COVID.
So, what does this have to do with the CDC, the NIH, the pharmaceutical companies, and the Gates Foundation? They have all invested a lot in the production and success of COVID vaccines. Billions ride on its successful completion and administration around the world. And let’s not forget that Pfizer and the Bill and Melinda Gates Foundations are major donors for the CDC and NIH. If effective prophylactics and therapies tame Covid and drastically reduce the death toll, there would be less demand for the vaccine.. I wonder if Pfizer and the Gates Foundation would still be willing to donate if the CDC and NIH were funding studies and promoting the use of these cheap, generic drugs as an alternative to vaccines?
Hydroxychloroquine is $37 for a bottle of 100 pills. Budesonide is between 75 and 350 dollars for an inhaler which has 50-200 doses. Ivermectin costs around 80 dollars for 20 pills. Far less of a profit then they would get from a vaccine. And remember, besides Ivermectin, which can be given as a prophylactic, these treatments would only be given to those who were diagnosed with COVID, which would be a far smaller portion of the population. Clearly, we can see why the vaccine has a much greater financial appeal to some powerful health sector actors.